$17.33
1.82% yesterday
Nasdaq, Nov 15, 10:01 pm CET
ISIN
US8162121045
Symbol
RNAC
Sector
Industry

Cartesian Therapeutics Stock price

$17.33
-3.30 16.00% 1M
-9.32 34.97% 6M
-3.35 16.21% YTD
+2.79 19.16% 1Y
-36.52 67.82% 3Y
-3.67 17.48% 5Y
-192.67 91.75% 10Y
Nasdaq, Closing price Fri, Nov 15 2024
+0.31 1.82%
ISIN
US8162121045
Symbol
RNAC
Sector
Industry

Key metrics

Market capitalization $440.44m
Enterprise Value $235.89m
P/E (TTM) P/E ratio negative
EV/FCF (TTM) EV/FCF negative
EV/Sales (TTM) EV/Sales 4.92
P/S ratio (TTM) P/S ratio 9.19
P/B ratio (TTM) P/B ratio 550.68
Revenue growth (TTM) Revenue growth 38.82%
Revenue (TTM) Revenue $47.94m
EBIT (operating result TTM) EBIT $-52.71m
Free Cash Flow (TTM) Free Cash Flow $-48.41m
Cash position $219.20m
EPS (TTM) EPS $-52.64
P/E forward negative
P/S forward 10.85
EV/Sales forward 5.72
Short interest 13.35%
Show more

Is Cartesian Therapeutics a Top Scorer Stock based on the Dividend, High-Growth-Investing or Leverman Strategy?

As a Free StocksGuide user, you can view scores for all 6,897 stocks worldwide.

Cartesian Therapeutics Stock Analysis

Unlock Scores for Free

Analyst Opinions

6 Analysts have issued a Cartesian Therapeutics forecast:

5x Buy
83%
1x Hold
17%

Analyst Opinions

6 Analysts have issued a Cartesian Therapeutics forecast:

Buy
83%
Hold
17%

Financial data from Cartesian Therapeutics

Income Statement P&L | Balance Sheet | Cash Flow


Quarter TTM Annually
Sep '24
+/-
%
48 48
39% 39%
100%
- Direct Costs 0.94 0.94
54% 54%
2%
47 47
45% 45%
98%
- Selling and Administrative Expenses 43 43
107% 107%
89%
- Research and Development Expense 56 56
18% 18%
117%
-52 -52
8% 8%
-108%
- Depreciation and Amortization 0.94 0.94
54% 54%
2%
EBIT (Operating Income) EBIT -53 -53
10% 10%
-110%
Net Profit -287 -287
693% 693%
-598%

In millions USD.

Don't miss a Thing! We will send you all news about Cartesian Therapeutics directly to your mailbox free of charge.

If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.

Cartesian Therapeutics Stock News

Negative
Seeking Alpha
5 days ago
Cartesian Therapeutics' stock has rebounded sharply recently despite no significant news, driven partly by insider buying after a disappointing Phase 2b trial for Descartes-08 in myasthenia gravis. The company leverages its RNA Armory platform for mRNA cell therapies, focusing on autoimmune diseases, with Descartes-08 and Descartes-15 as its main assets. Descartes-08 showed mixed results in Pha...
Neutral
GlobeNewsWire
8 days ago
FREDERICK, Md., Nov. 08, 2024 (GLOBE NEWSWIRE) -- Cartesian Therapeutics, Inc. (NASDAQ: RNAC) (the “Company”), a clinical-stage biotechnology company pioneering mRNA cell therapies for the treatment of autoimmune diseases, today announced the granting of inducement awards to two new employees. On November 4, 2024, the Company issued to these employees options to purchase an aggregate of 4,854 s...
Neutral
GlobeNewsWire
about one month ago
Company continues to expect to hold an End-of-Phase 2 meeting with the FDA by year-end Company continues to expect to hold an End-of-Phase 2 meeting with the FDA by year-end
More Cartesian Therapeutics News

Company Profile

Selecta Biosciences, Inc. operates as a clinical-stage biopharmaceutical company, which engages in the research and development of nanoparticle immunomodulatory drugs for the treatment and prevention of human diseases. It produces the Synthetic Vaccine Particles (SVP) platform for immune tolerance and immune stimulation. The firm's proprietary pipeline includes SVP-enabled enzyme, oncology and gene therapies. The company was founded by Omid C. Farokhzad, Robert S. Langer Jr., and Ulrich von Andrian in 2007 and is headquartered in Watertown, MA.

Head office United States
CEO Carsten Brunn
Employees 38
Founded 2007
Website www.cartesiantherapeutics.com

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

The Apple stock at a glance with charts, current key metrics, news and stock analyses.
The Best Dividend Stocks in the Dividend Top Scorer list.
Stock Analyses of the Best Stocks Worldwide.
Start building wealth today